They found that in the presence of CD133+ CSCs, CD133− cancer cells undergo an epithelial-mesenchymal transition (EMT)-like process and display enhanced metastatic capacity in in vitro assays as well as in vivo xenografts. The gene discussed is PROM1; the disease is cancer.